When to Take Sermorelin: Why Bedtime Is Common

When to take sermorelin usually means near bedtime. That timing is meant to line up with the body's largest natural growth-hormone pulse, which commonly begins soon after deep sleep starts. But bedtime is a convention, not a universal rule. Morning doses of growth hormone-releasing hormone (GHRH), the natural signal sermorelin copies, have produced a growth-hormone response in a small human study. No good adult trial has shown that the same clock time is best for everyone. The prescription should settle both timing and frequency.

When to take sermorelin: why bedtime is common

Growth hormone is released in bursts, not as a steady stream. The largest burst is closely tied to slow-wave sleep, the deepest stage of sleep. That is why the useful landmark is sleep onset, not a magic hour such as 9 p.m.

The classic evidence is wonderfully direct. Researchers monitored eight young adults across 38 nights. In seven of them, a major growth-hormone peak appeared with the start of deep sleep and lasted 1.5 to 3.5 hours. When sleep was delayed, the peak moved later too (Takahashi and colleagues, Journal of Clinical Investigation, 1968).

Sermorelin is a GHRH analogue, a shorter copy of that natural hormone. It asks the pituitary gland, a small gland below the brain, to release growth hormone. Bedtime is intended to place that signal near a natural opening, rather than make the body release hormone continuously.

That explanation is a rationale, not a promise that bedtime works better for every adult. Age, sleep disruption, shift work and pituitary function can all change the background rhythm.

What the sermorelin studies actually did

The older studies used nighttime schedules, but they weren't designed to settle morning versus night for adults.

The main pediatric study behind Geref followed 110 children with growth-hormone deficiency for up to one year. It used a once-daily injection under the skin at bedtime (Thorner and colleagues, Journal of Clinical Endocrinology & Metabolism, 1996). That tells us what the study did. It does not turn a 1990s pediatric schedule into a current adult instruction.

An adult study took a similar approach. Eleven healthy men ages 64 to 76 used GHRH(1-29), the peptide sequence in sermorelin, nightly for six weeks. Nighttime growth-hormone release rose, while IGF-1, a steadier blood marker of growth-hormone signaling, did not change significantly (Vittone and colleagues, Metabolism, 1997). There was no morning comparison group.

So the research explains how bedtime became standard practice. It does not prove that a morning prescription cannot work.

Can sermorelin be taken in the morning?

Morning is biologically possible, but the direct evidence is thin. In a 1997 sleep-laboratory study, seven healthy young men received four doses of GHRH through a vein between 4 a.m. and 7 a.m. Growth-hormone levels increased significantly, while most recorded sleep measures did not change (Schier and colleagues, Journal of Neuroendocrinology, 1997).

That study is useful because it shows the pituitary can respond in the early morning. It is also easy to overread. The researchers used repeated doses through a vein in a lab, not one under-the-skin dose from a current adult sermorelin prescription.

A provider may consider a morning schedule when bedtime timing does not fit a person's sleep pattern or causes a practical problem. For a night-shift worker, “bedtime” may occur after sunrise. What matters is the plan the prescriber wrote, not whether the clock says morning or evening.

Hunger is a different hormone story

Sermorelin is not a ghrelin mimetic, meaning it does not copy the hunger-linked hormone ghrelin. It acts at the GHRH receptor. Ipamorelin acts at the ghrelin receptor instead; sermorelin versus ipamorelin explains those two pathways in plain terms.

The difference matters because ghrelin itself can increase appetite. In a study that gave all nine healthy adults both ghrelin and saltwater in random order, ghrelin delivered through a vein increased average food intake by 28% (Wren and colleagues, Journal of Clinical Endocrinology & Metabolism, 2001). That is evidence about ghrelin, not evidence that sermorelin causes hunger.

A new appetite change still deserves review rather than being dismissed. It could relate to the wider treatment plan, another medicine, sleep loss or something unrelated. A CJC-1295/ipamorelin prescription also uses two different molecules—another GHRH analogue and ipamorelin—so its timing and appetite discussion should not be copied from a sermorelin schedule.

Does sermorelin make you sleepy?

Sermorelin is not established as a sedative. The confusion makes sense, though: GHRH biology and sleep are closely connected.

One small human experiment compared four separated nighttime GHRH doses with a steady dose through a vein and an inactive comparison. The separated doses increased deep sleep and REM sleep, the stage when vivid dreams are common, while the steady dose generally did not (Steiger and colleagues, Journal of Clinical Endocrinology & Metabolism, 1996). The study did not test current compounded sermorelin or measure a reliable rate of next-day drowsiness.

That leaves a careful answer: feeling sleepy is possible, but the published evidence cannot tell a person to expect it or prove that sermorelin caused it. A strong or persistent change in alertness belongs in the prescriber's review, especially when other medicines or disrupted sleep are involved.

Frequency belongs to the prescription

Timing and frequency are separate questions. A short signal near sleep does not automatically answer how many days per week a prescription should cover. The formulation, concentration, clinical purpose, response and tolerability all matter. How prescribers set sermorelin dosing covers that decision without turning old study schedules into instructions.

A compounded medicine is prepared by a licensed pharmacy for an individual prescription. No FDA-approved sermorelin product is currently marketed—Geref's treatment product was approved in 1997 and its approval was withdrawn in 2009—and the compounded formulation offered here is not FDA-approved. FDA later determined that the discontinued Geref products were not withdrawn for safety or effectiveness reasons (Federal Register, March 4, 2013). A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

At Promise, a licensed provider reviews every request, sets the actual schedule and may prescribe or decline based on medical eligibility. Not everyone qualifies.

The practical answer

Bedtime is the usual starting convention because sleep onset and the largest natural growth-hormone pulse tend to travel together. Morning is not automatically ineffective, and sleepiness or hunger should not be assumed from the clock alone. The right time is the one on the prescription, built around the person's real sleep pattern and medical picture. Evening routines often include a drink, and sermorelin and alcohol explains why that matters for the overnight pulse.